- Home
- ARCT vs ERAS Comparison
ARCT vs ERAS Comparison
Compare ARCT & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARCT
- ERAS
- Stock Information
- Founded
- ARCT 2013
- ERAS 2018
- Country
- ARCT United States
- ERAS United States
- Employees
- ARCT N/A
- ERAS N/A
- Industry
- ARCT Biotechnology: Pharmaceutical Preparations
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- ARCT Health Care
- ERAS Health Care
- Exchange
- ARCT Nasdaq
- ERAS Nasdaq
- Market Cap
- ARCT 602.7M
- ERAS 719.0M
- IPO Year
- ARCT N/A
- ERAS 2021
- Fundamental
- Price
- ARCT $16.02
- ERAS $2.67
- Analyst Decision
- ARCT Strong Buy
- ERAS Strong Buy
- Analyst Count
- ARCT 7
- ERAS 5
- Target Price
- ARCT $65.00
- ERAS $6.10
- AVG Volume (30 Days)
- ARCT 400.2K
- ERAS 1.7M
- Earning Date
- ARCT 11-07-2024
- ERAS 11-12-2024
- Dividend Yield
- ARCT N/A
- ERAS N/A
- EPS Growth
- ARCT N/A
- ERAS N/A
- EPS
- ARCT N/A
- ERAS N/A
- Revenue
- ARCT $160,399,000.00
- ERAS N/A
- Revenue This Year
- ARCT $13.02
- ERAS N/A
- Revenue Next Year
- ARCT $5.58
- ERAS N/A
- P/E Ratio
- ARCT N/A
- ERAS N/A
- Revenue Growth
- ARCT N/A
- ERAS N/A
- 52 Week Low
- ARCT $14.93
- ERAS $1.51
- 52 Week High
- ARCT $45.00
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- ARCT 31.24
- ERAS 43.56
- Support Level
- ARCT $18.90
- ERAS $2.59
- Resistance Level
- ARCT $21.61
- ERAS $3.19
- Average True Range (ATR)
- ARCT 1.15
- ERAS 0.20
- MACD
- ARCT -0.07
- ERAS -0.02
- Stochastic Oscillator
- ARCT 16.32
- ERAS 20.13
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.